Raymond James & Associates Regenxbio Inc. Transaction History
Raymond James & Associates
- $146 Billion
- Q1 2024
A detailed history of Raymond James & Associates transactions in Regenxbio Inc. stock. As of the latest transaction made, Raymond James & Associates holds 55,149 shares of RGNX stock, worth $584,027. This represents 0.0% of its overall portfolio holdings.
Number of Shares
55,149
Previous 50,537
9.13%
Holding current value
$584,027
Previous $907,000
28.0%
% of portfolio
0.0%
Previous 0.0%
Shares
24 transactions
Others Institutions Holding RGNX
# of Institutions
193Shares Held
42.1MCall Options Held
80.6KPut Options Held
55.2K-
Black Rock Inc. New York, NY7.6MShares$80.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.88MShares$51.6 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.55MShares$48.2 Million3.78% of portfolio
-
Jpmorgan Chase & CO New York, NY3.72MShares$39.4 Million0.01% of portfolio
-
State Street Corp Boston, MA3.12MShares$33.1 Million0.0% of portfolio
About REGENXBIO Inc.
- Ticker RGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,230,000
- Market Cap $458M
- Description
- REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...